[Experimental models of immunochemotherapeutic synergism: study of the influence of the treatment schedule].
Graded doses of LSTPA or L1210 leukemia cells were injected ip or iv into fully compatible hosts or mice incompatible for Multiple Minor Histocompatibility Loci (MMHL). Three days later the animals were treated with single doses of BCNU, NM, DTIC and VCR. The results showed that NM and VCR could synergize with the weak anti-tumor immune responses of MMHL-histocompatible mice only upon ip injection of the tumor. If the same tumor has been injected iv, only BCNU could synergize with the host's antitumor response. On DTIC treatment, no synergistic effects were detectable for either route of tumor's challenge.
D000818:Animals; D000912:Antibodies, Neoplasm / Q000032:analysis; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004357:Drug Synergism; D007167:Immunotherapy; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007942:Leukemia, Experimental / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy
D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents
Modelli sperimentali di sinergismo immunochemioterapico: studio della influenza dello schema di trattamento.